EXTON, Pa., June 2, 2016 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs and safety testing of medical devices, announces a new service offering for pre-clinical formulation evaluation: the In Vitro Dissolution Absorption System (IDAS™), a novel technology, unique to Absorption Systems, which enables the simultaneous evaluation of both formulation dissolution and drug absorption. Industry analysts predict high demand for IDAS™ services, based on its novel test system design.
Now pharmaceutical scientists will be able to rapidly evaluate two fundamental properties of a drug product at the same time: absorption rate across a human intestinal cell monolayer, which is an intrinsic property of the dissolved drug substance (active pharmaceutical ingredient or API), and dissolution rate, which is determined by the formulation (excipients) in which the active ingredient is packaged.
The ability to rapidly screen oral formulations for both dissolution and permeability simultaneously in an in vitro format will improve the reliability of pre-clinical formulation testing, leading to better decisions concerning formulations that should be evaluated in humans. The IDAS configuration allows for the assessment of many formulations at the same time. An added benefit is that the human intestinal cell permeability barrier used in IDAS is the same barrier that Absorption Systems uses for its world-renowned BCS permeability classification assay service.
Dr. Hidalgo commented that "We are really excited about IDAS because by integrating dissolution and permeability measurements we could assess the absorption potential of a drug from a solid formulation, making it possible to predict in vivo performance of actual drug products, something that has not been feasible with any in vitro system until now. It's very clear that this technology will help get more effective and safer drugs to patients sooner."
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. IDAS™, a novel in vitro test system for simultaneous screening of drug absorption and dissolution, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for formulation assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Panama, serves customers throughout the world. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/absorption-systems-announces-idas-the-only-system-for-simultaneous-evaluation-of-dissolution-and-permeability-300278415.html
SOURCE Absorption Systems